Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Arca Biopharma Inc

(NASDAQ: ABIO)
Add to Portfolio
-0.11 (-1.92%)
as of Sep 20, 2019

Last 5.63
Change -0.11 (-1.92%)
Open 5.64
Prev. Close 5.74
Today's Range
5.51
5.78
52wk Range
4.68
20.45
Volume 41,600
Avg Volume 163,365
Sector SIC-2835 In Vitro & In Vivo Diagnostic Substances

Perfomance Comparison

Name Today 3-Month 1-Year
ABIO -1.92% -18.05% -39.85%
DJIA -0.59% -0.56% +1.04%
S&P 500 -0.49% -0.26% +2.09%

Key Statistics

Annual EPS -6.78
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 8,350
Weighted Alpha -52.10
Standard Deviation -0.38
Profit Margin N/A
Beta 1.84

Growth Rates

YTD -5.22%
1-Year -38.67%
3-Year -89.03%
5-Year -96.21%
10-Year -99.79%

Opinion

Sell Hold Buy

Recent Headlines

ARCA Biopharma President and CEO Dr. Michael Bristow

GlobeNewswire via COMTEX - Thu Sep 12, 08:30AM EDT
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that Dr. Michael Bristow, President (full story)
ABIO: 5.63 (-0.11)

Arca Biopharma Announces Gencaro Atrial Fibrillation

GlobeNewswire via COMTEX - Wed Sep 11, 08:30AM EDT
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that Gencaro atrial fibrillation cli(full story)
ABIO: 5.63 (-0.11)

INVESTOR ACTION NOTICE: The Schall Law Firm Announces

GlobeNewswire via COMTEX - Wed Aug 21, 09:49AM EDT
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Abiomed, Inc. ("Abiomed" or "the Company") (NASDAQ: ABMD) for violations of §§10(b)(full story)
ABMD: 192.76 (+0.44), ABIO: 5.63 (-0.11)

ARCA biopharma Announces Second Quarter 2019 Financial

GlobeNewswire via COMTEX - Thu Aug 01, 04:30PM EDT
-- FDA SPA Agreement for Phase 3 atrial fibrillation trial (PRECISION-AF) amended to expand patient population to include heart failure patients with preserved ejection fraction (HFpEF)(full story)
ABIO: 5.63 (-0.11)

ARCA biopharma Announces Submission of Patent

GlobeNewswire via COMTEX - Mon May 13, 09:01AM EDT
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced it recently filed a provisional pate(full story)
ABIO: 5.63 (-0.11)